TOPICORT LP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TOPICORT LP (TOPICORT LP).
Topicort LP (desoximetasone) is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to intracellular glucocorticoid receptors, leading to modulation of gene expression that suppresses inflammatory mediators such as prostaglandins, leukotrienes, and cytokines.
| Metabolism | Topical corticosteroids are metabolized primarily in the skin and then systemically via hepatic pathways, including glucuronidation and sulfation, with subsequent renal excretion. |
| Excretion | Primarily renal (urinary excretion of metabolites and unchanged drug). Biliary/fecal elimination is minimal, accounting for <5% of the dose. |
| Half-life | Terminal elimination half-life is approximately 2-4 hours after topical application. This short half-life reflects rapid systemic clearance and minimal accumulation with once-daily dosing. |
| Protein binding | Approximately 90% bound primarily to albumin and corticosteroid-binding globulin (transcortin). |
| Volume of Distribution | Volume of distribution is not well-defined for topical corticosteroids; systemic absorption is minimal, and Vd is not typically reported. After systemic absorption, corticosteroids distribute widely; for betamethasone dipropionate, the apparent Vd is approximately 1-2 L/kg. |
| Bioavailability | Topical application: Systemic bioavailability is <5% under normal conditions (intact skin). Bioavailability increases with occlusive dressings, inflamed skin, or use on large surface areas. No oral or parenteral bioavailability data are clinically relevant for this topical product. |
| Onset of Action | Topical application: Onset of clinical effect (e.g., reduction of inflammation and pruritus) is typically within 1-2 weeks of twice-daily application. For occlusion therapy, onset may be faster (3-7 days). |
| Duration of Action | Topical application: Duration of clinical effect after a single application is approximately 12-24 hours, supporting once- or twice-daily dosing. Prolonged use may lead to tachyphylaxis. |
| Molecular Weight | 376.46 |
Apply a thin film to the affected skin areas twice daily. Route: topical. Frequency: twice daily.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment; minimal systemic absorption. |
| Liver impairment | No dose adjustment required for hepatic impairment; minimal systemic absorption. |
| Pediatric use | Use lowest effective dose for shortest duration; apply sparingly to limited areas. Not recommended for children under 2 years due to increased systemic absorption. |
| Geriatric use | Use with caution; apply sparingly to limited areas due to thinner skin and increased potential for systemic effects. |
| 1st trimester | Topical corticosteroids are generally avoided in first trimester unless benefits outweigh risks; limited data suggest no major teratogenic risk with low potency. TOPICORT LP (desoximetasone) is a moderate potency corticosteroid; use only if clearly needed. |
| 2nd trimester | May be used cautiously with small amounts over limited areas. Prolonged use or large areas may increase risk of fetal growth restriction. |
| 3rd trimester | Use only if necessary; prolonged use may cause fetal adrenal suppression or growth retardation. Avoid high doses over large areas. |
Clinical note
Comprehensive clinical and safety monograph for TOPICORT LP (TOPICORT LP).
| Placental transfer | Topical corticosteroids cross placenta via passive diffusion; degree depends on potency, application area, duration, and skin integrity. Desoximetasone is a moderate potency corticosteroid; systemic absorption is low (estimated <1% of applied dose), but prolonged use over large areas may increase transfer. |
| Breastfeeding |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to desoximetasone or any component of the formulationUntreated bacterial, fungal, or viral skin infections (e.g., herpes, varicella)
| Precautions | Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with potential for glucocorticosteroid insufficiency after withdrawal., Use in children may increase susceptibility to systemic toxicity due to higher skin surface-to-body mass ratio., Avoid prolonged use on face, intertriginous areas, or under occlusive dressings., Local adverse reactions include atrophy, striae, telangiectasias, and allergic contact dermatitis. |
| Food/Dietary | No known food interactions. Systemic absorption is minimal with topical use; dietary restrictions are not required. |
Loading safety data…
| Topical administration of desoximetasone results in minimal systemic absorption. Avoid application to breast area to prevent infant ingestion. Use lowest effective dose for shortest duration. No adverse effects reported in breastfed infants. |
| Lactation Rating | L2 (Safer) - Limited data but likely safe when used appropriately. |
| Teratogenic Risk | Topical corticosteroids, including TOPICORT LP (desoximetasone), are generally considered low risk for teratogenicity when used sparingly on small areas. However, first trimester use is associated with a small increased risk of orofacial clefts (odds ratio ~1.3). Second and third trimester use may cause fetal growth restriction and adrenal suppression if large amounts are used systemically. Use lowest potency for shortest duration. |
| Fetal Monitoring | Monitor fetal growth via ultrasound if prolonged use over large body surface area. Assess maternal adrenal function (ACTH stimulation test) if high-potency or extensive use. Observe neonate for signs of adrenal suppression if maternal use near term or in high doses. |
| Fertility Effects | No known adverse effects on fertility in animal studies. No human data available. |
| Clinical Pearls | TOPICORT LP (desoximetasone 0.05%) is a low-potency topical corticosteroid, classified as Class IV on the United States potency scale. It is suitable for maintenance therapy or for sensitive skin areas (face, intertriginous regions) after initial control with a higher potency agent. Limit continuous use to 2 weeks; avoid application to broken skin, large body surface areas (>20%), or under occlusion unless directed. Monitor for skin atrophy, striae, and telangiectasias with prolonged use. |
| Patient Advice | Apply a thin layer only to affected skin areas; do not use on healthy skin. · Do not cover the treated area with bandages, wraps, or dressings unless instructed by your doctor. · Wash hands before and after application to avoid spreading the medicine to other areas or people. · Avoid contact with eyes, mouth, and genital areas; if accidental contact occurs, rinse with water. · Use only for the prescribed duration; do not use for more than 2 weeks without reevaluation. · Inform your doctor if you develop signs of infection, skin thinning, or unusual bruising. · Do not use for children's diaper rash unless directed; avoid using large amounts or under tight diapers. |